Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents... Show more
Thermo Fisher Scientific shares have traded in a relatively measured range in recent weeks, hovering near the $698 level after a modest climb of roughly 6% over the trailing month. The move reflects a gradual repricing rather than a sharp re-rating, as investors weigh an improving life sciences demand environment against a valuation that remains above the stock's longer-term historical average. The shares have been supported by a stronger-than-expected third-quarter report and a steady stream of analyst price-target increases following the results, while some brokers have held more cautious ratings given the stock's premium multiple. Within the healthcare and life sciences tools sector, Thermo Fisher continues to be viewed as a bellwether for biotech funding trends and pharmaceutical research-and-development spending, making its share price a useful gauge of broader sector sentiment.
Thermo Fisher Scientific is one of the world's largest life sciences tools and services companies, with annual revenue exceeding $45 billion. The company serves pharmaceutical and biotechnology customers, hospitals and clinical laboratories, academic and government institutions, and industrial clients through four reportable segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its portfolio spans well-known brands including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
The company's competitive strength rests on a diversified mix of consumables, instruments, and outsourced pharma services, which provides recurring revenue and exposure to multiple points along the drug development and manufacturing value chain. Its scale, global distribution, and track record of disciplined acquisitions position it alongside peers such as Danaher (DHR) and Agilent Technologies (A) at the center of the life sciences industry. Investors follow TMO closely because its results are widely read as a signal of underlying demand across biopharmaceutical research, clinical diagnostics, and advanced manufacturing.
Thermo Fisher's third-quarter 2026 results, reported in late October, provided the primary catalyst for the stock's recent move. Revenue grew 9% to $12.14 billion, with organic growth of 6%, while adjusted operating income rose 15% to $2.97 billion and adjusted operating margin expanded 120 basis points to 24.5%. Adjusted EPS of $6.68 came in ahead of consensus, and GAAP diluted EPS increased 9% to $4.64. Management noted that the improved end-market conditions seen in the second quarter carried into the third, led by high single-digit growth in pharma and biotech and strength in electron microscopy tied to semiconductor demand.
Alongside the results, the company raised its full-year 2026 outlook to revenue of $47.7–$48.2 billion and adjusted EPS of $25.13–$25.43, representing 10%–11% EPS growth. The quarter also benefited from roughly $60 million in net tariff refund recoveries, or about $0.15 of adjusted EPS, which the company said it partly reinvested in AI deployment and new capacity. Strategically, Thermo Fisher completed its divestiture of the microbiology business and reported smooth integration of the Clario acquisition, a clinical-trials data provider acquired earlier in 2026 for $8.875 billion in cash. Following the report, several analysts issued or reiterated Buy ratings, with price targets ranging into the mid-$700s, while at least one broker moved to a Hold rating.
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a platform that offers hundreds of bots trading thousands of tickers. Rather than listing every available strategy, this section surfaces only the top-performing and most relevant bots, helping users cut through the noise. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term swing approaches to longer-horizon systems, so investors can explore options that align with different risk profiles and goals. The page is designed to give a snapshot of what is currently working across the platform, and visitors can review individual bot performance before deciding whether to explore further.
Looking ahead, the central question for Thermo Fisher is whether the biotech funding recovery and improving pharma-services demand can sustain the acceleration seen in the third quarter. Management has guided to roughly 4% organic growth in the fourth quarter, a step down from the 6% posted in Q3, in part due to customer activity timing, and has said its goal is to return to a more normalized mid-single-digit-to-higher growth environment toward 2027. Investors should monitor biotech financing activity, academic and government spending, and the pace of new instrument placements, as well as the integration and revenue synergies from Clario.
Macroeconomic factors such as interest rates, trade policy, and currency movements also remain relevant to a globally diversified operator. The company is scheduled to report fourth-quarter and full-year results and provide 2027 guidance in early February, which will be a key test of the durability of the current recovery narrative. As always, valuation remains a consideration, with the stock trading at a premium to its historical earnings multiple even as fundamentals improve.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TMO advanced for three days, in 192 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on TMO as a result. In 51 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 152 of 253 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 22 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.876) is normal, around the industry mean (67.298). P/E Ratio (37.333) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties